Targeting PI3K Signaling in Acute Lymphoblastic Leukemia
Abstract
:1. Introduction
2. Isoforms of PI3K
3. Regulation of PI3K Signaling
4. Role of PI3Kδ in Normal B-Cells
5. Role of PI3Kδ in ALL
6. Preclinical Inhibition of PI3K/PI3Kδ in ALL
7. PI3K Targeting Drugs in Clinical Trials
8. PI3K Inhibitors in Clinical Trial in ALL
9. Discussion
Author Contributions
Acknowledgments
Conflicts of Interest
References
- Roboz, G.J.; Jabbour, E.J.; Faderl, S.; Douer, D. Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: A case study compendium. Clin. Adv. Hematol. Oncol. 2014, 12, 8–18. [Google Scholar] [PubMed]
- Bhojwani, D.; Yang, J.J.; Pui, C.H. Biology of childhood acute lymphoblastic leukemia. Pediatr. Clin. N. Am. 2015, 62, 47–60. [Google Scholar] [CrossRef] [PubMed]
- Gaynon, P.S.; Qu, R.P.; Chappell, R.J.; Willoughby, M.L.; Tubergen, D.G.; Steinherz, P.G.; Trigg, M.E. Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse—The Children’s Cancer Group Experience. Cancer 1998, 82, 1387–1395. [Google Scholar] [CrossRef]
- Gaynon, P.S. Childhood acute lymphoblastic leukaemia and relapse. Br. J. Haematol. 2005, 131, 579–587. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Locatelli, F.; Schrappe, M.; Bernardo, M.E.; Rutella, S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012, 120, 2807–2816. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meads, M.B.; Hazlehurst, L.A.; Dalton, W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 2008, 14, 2519–2526. [Google Scholar] [CrossRef] [PubMed]
- Hazlehurst, L.A.; Dalton, W.S. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001, 20, 43–50. [Google Scholar] [CrossRef]
- Kumagai, M.; Manabe, A.; Pui, C.H.; Behm, F.G.; Raimondi, S.C.; Hancock, M.L.; Mahmoud, H.; Crist, W.M.; Campana, D. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J. Clin. Investig. 1996, 97, 755–760. [Google Scholar] [CrossRef]
- Manabe, A.; Coustan-Smith, E.; Behm, F.G.; Raimondi, S.C.; Campana, D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992, 79, 2370–2377. [Google Scholar]
- Mudry, R.E.; Fortney, J.E.; York, T.; Hall, B.M.; Gibson, L.F. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000, 96, 1926–1932. [Google Scholar]
- Tabe, Y.; Jin, L.; Tsutsumi-Ishii, Y.; Xu, Y.; McQueen, T.; Priebe, W.; Mills, G.B.; Ohsaka, A.; Nagaoka, I.; Andreeff, M.; et al. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 2007, 67, 684–694. [Google Scholar] [CrossRef] [PubMed]
- Morishita, N.; Tsukahara, H.; Chayama, K.; Ishida, T.; Washio, K.; Miyamura, T.; Yamashita, N.; Oda, M.; Morishima, T. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr. Blood Cancer 2012, 59, 83–89. [Google Scholar] [CrossRef] [PubMed]
- Hoellenriegel, J.; Meadows, S.A.; Sivina, M.; Wierda, W.G.; Kantarjian, H.; Keating, M.J.; Giese, N.; O’Brien, S.; Yu, A.; Miller, L.L.; et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118, 3603–3612. [Google Scholar] [CrossRef] [PubMed]
- Billottet, C.; Grandage, V.L.; Gale, R.E.; Quattropani, A.; Rommel, C.; Vanhaesebroeck, B.; Khwaja, A. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006, 25, 6648–6659. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, L.X.; Sesay, A.; Mitchell, B.S. Effect of CAL-101, a PI3Kdelta inhibitor, on ribosomal rna synthesis and cell proliferation in acute myeloid leukemia cells. Blood Cancer J. 2014, 4, e228. [Google Scholar] [CrossRef] [PubMed]
- Adam, E.; Kim, H.N.; Gang, E.J.; Schnair, C.; Lee, S.; Lee, S.; Khazal, S.; Kosoyan, O.; Konopleva, M.; Parekh, C.; et al. The PI3Kdelta Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL. Cancers 2017, 9, 121. [Google Scholar] [CrossRef] [PubMed]
- Burris, H.A., 3rd. Overcoming acquired resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR pathway. Cancer Chemother. Pharmacol. 2013, 71, 829–842. [Google Scholar] [CrossRef]
- Greenwell, I.B.; Flowers, C.R.; Blum, K.A.; Cohen, J.B. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: Today and tomorrow. Expert Rev. Anticancer Ther. 2017, 17, 271–279. [Google Scholar] [CrossRef]
- Greenwell, I.B.; Ip, A.; Cohen, J.B. PI3K Inhibitors: Understanding Toxicity Mechanisms and Management. Oncology (Williston Park) 2017, 31, 821–828. [Google Scholar]
- Thorpe, L.M.; Yuzugullu, H.; Zhao, J.J. PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 2015, 15, 7–24. [Google Scholar] [CrossRef]
- Kok, K.; Nock, G.E.; Verrall, E.A.; Mitchell, M.P.; Hommes, D.W.; Peppelenbosch, M.P.; Vanhaesebroeck, B. Regulation of p110delta PI 3-kinase gene expression. PLoS ONE 2009, 4, e5145. [Google Scholar] [CrossRef] [PubMed]
- Piddock, R.E.; Bowles, K.M.; Rushworth, S.A. The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. Cancers (Basel) 2017, 9, 29. [Google Scholar] [CrossRef] [PubMed]
- Conte, E.; Gili, E.; Fruciano, M.; Korfei, M.; Fagone, E.; Iemmolo, M.; Lo Furno, D.; Giuffrida, R.; Crimi, N.; Guenther, A.; et al. PI3K p110gamma overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: In vitro effects of its inhibition. Lab. Investig. 2013, 93, 566–576. [Google Scholar] [CrossRef]
- Wang, X.; Ding, J.; Meng, L.H. PI3K isoform-selective inhibitors: Next-generation targeted cancer therapies. Acta Pharmacol. Sin. 2015, 36, 1170–1176. [Google Scholar] [CrossRef] [PubMed]
- Backer, J.M. The regulation and function of Class III PI3Ks: Novel roles for Vps34. Biochem. J. 2008, 410, 1–17. [Google Scholar] [CrossRef] [PubMed]
- Bongiovanni, D.; Saccomani, V.; Piovan, E. Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia. Int. J. Mol. Sci. 2017, 18, 1904. [Google Scholar] [CrossRef] [PubMed]
- Yuan, T.; Yang, Y.; Chen, J.; Li, W.; Li, W.; Zhang, Q.; Mi, Y.; Goswami, R.S.; You, J.Q.; Lin, D.; et al. Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: A novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD. Leukemia 2017, 31, 2355–2364. [Google Scholar] [CrossRef]
- Okkenhaug, K.; Burger, J.A. PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr. Top. Microbiol. Immunol. 2016, 393, 123–142. [Google Scholar] [CrossRef]
- Dal Porto, J.M.; Gauld, S.B.; Merrell, K.T.; Mills, D.; Pugh-Bernard, A.E.; Cambier, J. B cell antigen receptor signaling 101. Mol. Immunol. 2004, 41, 599–613. [Google Scholar] [CrossRef]
- Shishido, S.; Bonig, H.; Kim, Y.M. Role of integrin alpha4 in drug resistance of leukemia. Front. Oncol. 2014, 4, 99. [Google Scholar] [CrossRef]
- Srinivasan, L.; Sasaki, Y.; Calado, D.P.; Zhang, B.; Paik, J.H.; DePinho, R.A.; Kutok, J.L.; Kearney, J.F.; Otipoby, K.L.; Rajewsky, K. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139, 573–586. [Google Scholar] [CrossRef] [PubMed]
- Al-Alwan, M.M.; Okkenhaug, K.; Vanhaesebroeck, B.; Hayflick, J.S.; Marshall, A.J. Requirement for phosphoinositide 3-kinase p110delta signaling in B cell antigen receptor-mediated antigen presentation. J. Immunol. 2007, 178, 2328–2335. [Google Scholar] [CrossRef] [PubMed]
- Schweighoffer, E.; Tybulewicz, V.L. Signalling for B cell survival. Curr. Opin. Cell Biol. 2018, 51, 8–14. [Google Scholar] [CrossRef] [PubMed]
- Chantry, D.; Vojtek, A.; Kashishian, A.; Holtzman, D.A.; Wood, C.; Gray, P.W.; Cooper, J.A.; Hoekstra, M.F. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem. 1997, 272, 19236–19241. [Google Scholar] [CrossRef] [PubMed]
- Vanhaesebroeck, B.; Ali, K.; Bilancio, A.; Geering, B.; Foukas, L.C. Signalling by PI3K isoforms: Insights from gene-targeted mice. Trends Biochem. Sci. 2005, 30, 194–204. [Google Scholar] [CrossRef]
- Chen, Z.; Getahun, A.; Chen, X.; Dollin, Y.; Cambier, J.C.; Wang, J.H. Imbalanced PTEN and PI3K Signaling Impairs Class Switch Recombination. J. Immunol. 2015, 195, 5461–5471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reif, K.; Okkenhaug, K.; Sasaki, T.; Penninger, J.M.; Vanhaesebroeck, B.; Cyster, J.G. Cutting edge: Differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J. Immunol. 2004, 173, 2236–2240. [Google Scholar] [CrossRef] [PubMed]
- Pauls, S.D.; Lafarge, S.T.; Landego, I.; Zhang, T.; Marshall, A.J. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: Activation mechanisms, regulation and impact on cellular functions. Front Immunol 2012, 3, 224. [Google Scholar] [CrossRef] [PubMed]
- Jellusova, J.; Rickert, R.C. The PI3K pathway in B cell metabolism. Crit. Rev. Biochem. Mol. Biol. 2016, 51, 359–378. [Google Scholar] [CrossRef]
- Dornan, G.L.; Siempelkamp, B.D.; Jenkins, M.L.; Vadas, O.; Lucas, C.L.; Burke, J.E. Conformational disruption of PI3Kdelta regulation by immunodeficiency mutations in PIK3CD and PIK3R1. Proc. Natl. Acad. Sci. USA 2017, 114, 1982–1987. [Google Scholar] [CrossRef]
- Michalovich, D.; Nejentsev, S. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy. Front. Immunol. 2018, 9, 369. [Google Scholar] [CrossRef] [PubMed]
- Rao, V.K.; Webster, S.; Dalm, V.; Sediva, A.; van Hagen, P.M.; Holland, S.; Rosenzweig, S.D.; Christ, A.D.; Sloth, B.; Cabanski, M.; et al. Effective “activated PI3Kdelta syndrome”-targeted therapy with the PI3Kdelta inhibitor leniolisib. Blood 2017, 130, 2307–2316. [Google Scholar] [CrossRef] [PubMed]
- Terwilliger, T.; Abdul-Hay, M. Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer J. 2017, 7, e577. [Google Scholar] [CrossRef] [PubMed]
- Erb, T.J.; Brecht, V.; Fuchs, G.; Muller, M.; Alber, B.E. Carboxylation mechanism and stereochemistry of crotonyl-CoA carboxylase/reductase, a carboxylating enoyl-thioester reductase. Proc. Natl. Acad. Sci. USA 2009, 106, 8871–8876. [Google Scholar] [CrossRef] [Green Version]
- Montano, A.; Forero-Castro, M.; Marchena-Mendoza, D.; Benito, R.; Hernandez-Rivas, J.M. New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update. Cancers (Basel) 2018, 10, 110. [Google Scholar] [CrossRef] [PubMed]
- Fransecky, L.; Mochmann, L.H.; Baldus, C.D. Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol. Cell. Ther. 2015, 3, 2. [Google Scholar] [CrossRef] [PubMed]
- Konopleva, M.Y.; Jordan, C.T. Leukemia stem cells and microenvironment: Biology and therapeutic targeting. J. Clin. Oncol. 2011, 29, 591–599. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Fortney, J.E.; Gibson, L.F. Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt. Leuk. Res. 2004, 28, 733–742. [Google Scholar] [CrossRef]
- Muranyi, A.L.; Dedhar, S.; Hogge, D.E. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk. Res. 2010, 34, 1358–1365. [Google Scholar] [CrossRef]
- Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8, 627–644. [Google Scholar] [CrossRef] [Green Version]
- Fiorcari, S.; Brown, W.S.; McIntyre, B.W.; Estrov, Z.; Maffei, R.; O’Brien, S.; Sivina, M.; Hoellenriegel, J.; Wierda, W.G.; Keating, M.J.; et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS ONE 2013, 8, e83830. [Google Scholar] [CrossRef] [PubMed]
- Burger, J.A.; Okkenhaug, K. Haematological cancer: Idelalisib-targeting PI3Kdelta in patients with B-cell malignancies. Nat. Rev. Clin. Oncol. 2014, 11, 184–186. [Google Scholar] [CrossRef] [PubMed]
- Bassan, R.; Bourquin, J.P.; DeAngelo, D.J.; Chiaretti, S. New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. J. Clin. Oncol. 2018. [Google Scholar] [CrossRef] [PubMed]
- Bashash, D.; Safaroghli-Azar, A.; Dadashi, M.; Safa, M.; Momeny, M.; Ghaffari, S.H. Anti-tumor activity of PI3K-delta inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib. Int. J. Biochem. Cell Biol. 2017, 85, 149–158. [Google Scholar] [CrossRef] [PubMed]
- Gilbert, J.A. Idelalisib: Targeting PI3Kdelta in B-cell malignancies. Lancet Oncol. 2014, 15, e108. [Google Scholar] [CrossRef]
- Ali, A.Y.; Wu, X.; Eissa, N.; Hou, S.; Ghia, J.E.; Murooka, T.T.; Banerji, V.; Johnston, J.B.; Lin, F.; Gibson, S.B.; et al. Distinct roles for phosphoinositide 3-kinases gamma and delta in malignant B cell migration. Leukemia 2018, 32, 1958–1969. [Google Scholar] [CrossRef]
- Boer, J.M.; den Boer, M.L. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside. Eur. J. Cancer 2017, 82, 203–218. [Google Scholar] [CrossRef] [PubMed]
- Roberts, K.G.; Li, Y.; Payne-Turner, D.; Harvey, R.C.; Yang, Y.L.; Pei, D.; McCastlain, K.; Ding, L.; Lu, C.; Song, G.; et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 2014, 371, 1005–1015. [Google Scholar] [CrossRef]
- Radler, P.D.; Wehde, B.L.; Wagner, K.U. Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells. Mol. Cell. Endocrinol. 2017, 451, 31–39. [Google Scholar] [CrossRef]
- Bibi, S.; Arslanhan, M.D.; Langenfeld, F.; Jeanningros, S.; Cerny-Reiterer, S.; Hadzijusufovic, E.; Tchertanov, L.; Moriggl, R.; Valent, P.; Arock, M. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: Possible new targets of therapy. Haematologica 2014, 99, 417–429. [Google Scholar] [CrossRef]
- Schmidt, J.W.; Wehde, B.L.; Sakamoto, K.; Triplett, A.A.; Anderson, S.M.; Tsichlis, P.N.; Leone, G.; Wagner, K.U. Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis. Mol. Cell. Biol. 2014, 34, 1363–1377. [Google Scholar] [CrossRef] [PubMed]
- Kruth, K.A.; Fang, M.; Shelton, D.N.; Abu-Halawa, O.; Mahling, R.; Yang, H.; Weissman, J.S.; Loh, M.L.; Muschen, M.; Tasian, S.K.; et al. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood 2017, 129, 3000–3008. [Google Scholar] [CrossRef] [PubMed]
- Tasian, S.K.; Teachey, D.T.; Li, Y.; Shen, F.; Harvey, R.C.; Chen, I.M.; Ryan, T.; Vincent, T.L.; Willman, C.L.; Perl, A.E.; et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2017, 129, 177–187. [Google Scholar] [CrossRef]
- Jou, S.T.; Carpino, N.; Takahashi, Y.; Piekorz, R.; Chao, J.R.; Carpino, N.; Wang, D.; Ihle, J.N. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol. Cell. Biol. 2002, 22, 8580–8591. [Google Scholar] [CrossRef] [PubMed]
- Fruman, D.A.; Cantley, L.C. Idelalisib--a PI3Kdelta inhibitor for B-cell cancers. N. Engl. J. Med. 2014, 370, 1061–1062. [Google Scholar] [CrossRef]
- Eldfors, S.; Kuusanmaki, H.; Kontro, M.; Majumder, M.M.; Parsons, A.; Edgren, H.; Pemovska, T.; Kallioniemi, O.; Wennerberg, K.; Gokbuget, N.; et al. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. Leukemia 2017, 31, 51–57. [Google Scholar] [CrossRef] [PubMed]
- Safaroghli-Azar, A.; Bashash, D.; Sadreazami, P.; Momeny, M.; Ghaffari, S.H. PI3K-delta inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells. Anticancer Drugs 2017, 28, 436–445. [Google Scholar] [CrossRef]
- Yao, H.; Price, T.T.; Cantelli, G.; Ngo, B.; Warner, M.J.; Olivere, L.; Ridge, S.M.; Jablonski, E.M.; Therrien, J.; Tannheimer, S.; et al. Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature 2018, 560, 55–60. [Google Scholar] [CrossRef]
- Krause, G.; Hassenruck, F.; Hallek, M. Copanlisib for treatment of B-cell malignancies: The development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des. Dev. Ther. 2018, 12, 2577–2590. [Google Scholar] [CrossRef]
- Liu, X.; Wang, A.; Liang, X.; Chen, C.; Liu, J.; Zhao, Z.; Wu, H.; Deng, Y.; Wang, L.; Wang, B.; et al. Characterization of selective and potent PI3Kdelta inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget 2016, 7, 32641–32651. [Google Scholar] [CrossRef]
- Ultimo, S.; Simioni, C.; Martelli, A.M.; Zauli, G.; Evangelisti, C.; Celeghini, C.; McCubrey, J.A.; Marisi, G.; Ulivi, P.; Capitani, S.; et al. PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget 2017, 8, 23213–23227. [Google Scholar] [CrossRef] [PubMed]
- Evangelisti, C.; Cappellini, A.; Oliveira, M.; Fragoso, R.; Barata, J.T.; Bertaina, A.; Locatelli, F.; Simioni, C.; Neri, L.M.; Chiarini, F.; et al. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. J. Cell. Physiol. 2018, 233, 1796–1811. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.-S.; Ham, S.; Rai, K.R.; McGovern, K.; Kutok, J.L.; Chiorazzi, N. Dual Inhibition of PI3K-Delta and Gamma By Duvelisib (IPI-145) Impairs CLL B- and T-Cell Migration, Survival and Proliferation in a Murine Xenograft Model Using Primary Chronic Lymphocytic Leukemia Cells. Blood 2015, 126, 1753. [Google Scholar]
- Andrews, F.H.; Singh, A.R.; Joshi, S.; Smith, C.A.; Morales, G.A.; Garlich, J.R.; Durden, D.L.; Kutateladze, T.G. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 2017, 114, E1072–E1080. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.N.; Nichols, C.; Jiang, E.J.; Abdel-Azim, N.; Coba, A.; Durden, D.L.; Kim, Y.-M. Dual Targeting of PI3Kdelta and BRD4 Sensitizes Acute Lymphoblastic Leukemia to Chemotherapy. Blood 2018, 132, 1420. [Google Scholar] [CrossRef]
- Gazi, M.; Moharram, S.A.; Marhall, A.; Kazi, J.U. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). Cancer Lett. 2017, 392, 9–16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stefanzl, G.; Berger, D.; Cerny-Reiterer, S.; Blatt, K.; Eisenwort, G.; Sperr, W.R.; Hoermann, G.; Lind, K.; Hauswirth, A.W.; Bettelheim, P.; et al. The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. Oncotarget 2017, 8, 67709–67722. [Google Scholar] [CrossRef] [Green Version]
- Lonetti, A.; Cappellini, A.; Bertaina, A.; Locatelli, F.; Pession, A.; Buontempo, F.; Evangelisti, C.; Evangelisti, C.; Orsini, E.; Zambonin, L.; et al. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. J. Hematol. Oncol. 2016, 9, 114. [Google Scholar] [CrossRef]
- Lonetti, A.; Cappellini, A.; Sparta, A.M.; Chiarini, F.; Buontempo, F.; Evangelisti, C.; Evangelisti, C.; Orsini, E.; McCubrey, J.A.; Martelli, A.M. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Oncotarget 2015, 6, 10399–10414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miller, B.W.; Przepiorka, D.; de Claro, R.A.; Lee, K.; Nie, L.; Simpson, N.; Gudi, R.; Saber, H.; Shord, S.; Bullock, J.; et al. FDA approval: Idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin. Cancer Res. 2015, 21, 1525–1529. [Google Scholar] [CrossRef]
- Furman, R.R.; Sharman, J.P.; Coutre, S.E.; Cheson, B.D.; Pagel, J.M.; Hillmen, P.; Barrientos, J.C.; Zelenetz, A.D.; Kipps, T.J.; Flinn, I.; et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2014, 370, 997–1007. [Google Scholar] [CrossRef]
- Migault, C.; Lebrun, D.; Toubas, O.; Nguyen, Y.; Giltat, A.; Julien, G.; Toubas, D.; Lebargy, F.; Delmer, A.; Bani-Sadr, F. Pulmonary adverse events related to idelalisib therapy: A single centre experience. J. Chemother. 2018, 1–5. [Google Scholar] [CrossRef]
- Barr, P.M.; Saylors, G.B.; Spurgeon, S.E.; Cheson, B.D.; Greenwald, D.R.; O’Brien, S.M.; Liem, A.K.; McLntyre, R.E.; Joshi, A.; Abella-Dominicis, E.; et al. Phase 2 study of idelalisib and entospletinib: Pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 2016, 127, 2411–2415. [Google Scholar] [CrossRef] [PubMed]
- Rhodes, J.; Mato, A.; Sharman, J.P. Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. Curr. Oncol. Rep. 2018, 20, 49. [Google Scholar] [CrossRef] [PubMed]
- Mauro, F.R.; Caputo, M.D.; Rosati, S.; Pepe, S.; De Benedittis, D.; De Luca, M.L.; Foa, R. Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. Expert Rev. Hematol. 2018, 11, 601–611. [Google Scholar] [CrossRef]
- Mensah, F.A.; Blaize, J.P.; Bryan, L.J. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: Evidence to date. OncoTargets Ther. 2018, 11, 4817–4827. [Google Scholar] [CrossRef] [PubMed]
- Tang, L.A.; Dixon, B.N.; Maples, K.T.; Poppiti, K.M.; Peterson, T.J. Current and Investigational Agents Targeting the Phosphoinositide 3-Kinase Pathway. Pharmacotherapy 2018, 38, 1058–1067. [Google Scholar] [CrossRef]
- Flinn, I.W.; O’Brien, S.; Kahl, B.; Patel, M.; Oki, Y.; Foss, F.F.; Porcu, P.; Jones, J.; Burger, J.A.; Jain, N.; et al. Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies. Blood 2018, 131, 877–887. [Google Scholar] [CrossRef]
- Flinn, I.W.; Hillmen, P.; Montillo, M.; Nagy, Z.; Illes, A.; Etienne, G.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Gasztonyi, Z.; et al. The phase 3 DUO trial: Duvelisib versus ofatumumab in relapsed and refractory CLL/SLL. Blood 2018. [Google Scholar] [CrossRef]
- O’Brien, S.; Patel, M.; Kahl, B.S.; Horwitz, S.M.; Foss, F.M.; Porcu, P.; Jones, J.; Burger, J.; Jain, N.; Allen, K.; et al. Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am. J. Hematol. 2018, 93, 1318–1326. [Google Scholar] [CrossRef]
- Duvelisib Approved for Leukemia, Lymphoma. Cancer Discov. 2018. [CrossRef]
- Blair, H.A. Duvelisib: First Global Approval. Drugs 2018. [Google Scholar] [CrossRef] [PubMed]
- Flinn, I.W.; Miller, C.B.; Ardeshna, K.M.; Tetreault, S.; Assouline, S.E.; Zinzani, P.L.; Mayer, J.; Merli, M.; Lunin, S.D.; Pettitt, A.R.; et al. Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma. Blood 2016, 128, 1218. [Google Scholar]
- Ragon, B.K.; Kantarjian, H.; Jabbour, E.; Ravandi, F.; Cortes, J.; Borthakur, G.; DeBose, L.; Zeng, Z.; Schneider, H.; Pemmaraju, N.; et al. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am. J. Hematol. 2017, 92, 7–11. [Google Scholar] [CrossRef]
- Di Leo, A.; Johnston, S.; Lee, K.S.; Ciruelos, E.; Lonning, P.E.; Janni, W.; O’Regan, R.; Mouret-Reynier, M.A.; Kalev, D.; Egle, D.; et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018, 19, 87–100. [Google Scholar] [CrossRef]
Therapeutic Drug | Target (s) | Preclinical Model | Reference |
---|---|---|---|
Idelalisib (CAL101) | PI3Kδ inhibitor | B-ALL | [16,52,62,63,64,65] |
PI3KD-IN-015 | PI3Kδ inhibitor | B-ALL | [70] |
Duvelisib (ABBV-954, INK-1197, IPI-145) | PI3Kδ/PI3Kγ inhibitor | B-ALL | [72] |
SF2535 | PI3Kδ/BRD4 inhibitor | B-ALL | [75] |
PKI-587 | PI3K/mTOR inhibitor | T-ALL | [76] |
Dactolisib (BEZ235) | PI3K/mTOR inhibitor | B-ALL | [77] |
ZSTK-474 | PI3K pan- inhibitor | T-ALL | [78,79] |
Therapeutic Drug | Target (s) | Clinical Trial Status | Developer |
---|---|---|---|
Idelalisib (CAL101) | PI3Kδ inhibitor | FDA Approved | Gilead Sciences |
Copanlisib | Pan-class I PI3K inhibitor | FDA Approved | Aliqopa; Bayer |
Duvelisib (ABBV-954, INK-1197, IPI-145) | PI3Kδ/PI3Kγ inhibitor | FDA Approved | Copiktra; Verastem |
Therapeutic Drug | Target (s) | Clinical Trial Status | Developer | Clinical Trial Number |
---|---|---|---|---|
Buparlisib (BKM120) | Pan-PI3K inhibitor | Phase I | Novartis | NCT01396499 |
Dactolisib (BEZ235) | PI3K/mTOR inhibitor | Phase I | Novartis | NCT01756118 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sanchez, V.E.; Nichols, C.; Kim, H.N.; Gang, E.J.; Kim, Y.-M. Targeting PI3K Signaling in Acute Lymphoblastic Leukemia. Int. J. Mol. Sci. 2019, 20, 412. https://doi.org/10.3390/ijms20020412
Sanchez VE, Nichols C, Kim HN, Gang EJ, Kim Y-M. Targeting PI3K Signaling in Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. 2019; 20(2):412. https://doi.org/10.3390/ijms20020412
Chicago/Turabian StyleSanchez, Vanessa Edna, Cydney Nichols, Hye Na Kim, Eun Ji Gang, and Yong-Mi Kim. 2019. "Targeting PI3K Signaling in Acute Lymphoblastic Leukemia" International Journal of Molecular Sciences 20, no. 2: 412. https://doi.org/10.3390/ijms20020412